SPDR S&P Biotech ETF : XBI

Price Target

›

XBI

Stock Data

$130.42

$0.91 (0.69%)

Asset Type

N/A

Exchange

N/A

Currency

N/A

Country

N/A

Sector

N/A

Industry

N/A

All XBI Articles

9 Articles

Omor Ibne Ehsan | Apr 27, 2026 at 3:33 PM EDT

LABU Could Rip Higher if Biotech Finally Gets Its Long-Awaited Breakout

If you bought XBI a year ago and held it, you are up roughly 65%. If you bought Direxion Daily…

David Beren | Apr 23, 2026 at 1:22 PM EDT

Equal-Weight ETFs Are the Play for Small-Cap Drug Development. Here’s How to Position Now

Biotech has reasserted itself over the past year as drug approvals, obesity and GLP-1 programs, oncology pipelines, and renewed merger…

David Beren | Apr 7, 2026 at 10:20 AM EDT

XBI vs. IBB: The Biotech ETF Showdown That Analysts Say Has a Clear Winner in 2026

Biotech has long been one of the strongest sector stories of the past year, and investors who got there early…

John Seetoo | Apr 3, 2026 at 10:17 AM EDT

This Biotech ETF Is Still Well Below Its 2021 Peak. Analysts Say That Is Exactly Why to Buy It.

The biotech industry has been a robust roller-coaster over the last half decade. The State Street SPDR S&P Biotech ETF…

John Seetoo | Mar 31, 2026 at 10:50 AM EDT

Biotech Stocks Are Up About 35% in the Past Year and Analysts Say the Biggest Gains Are Still Ahead

The bulk of coverage towards the top gaining stock sectors over the past year has focused understandably on technology, which…

Michael Williams | Mar 29, 2026 at 8:15 AM EDT

MRNA, SRPT, and KRYS Phase 3 Data Will Shape XBI’s 2026 Performance

SPDR S&P Biotech ETF (NYSEARCA:XBI | XBI Price Prediction) is built around a deceptively simple idea: give every biotech company…

Michael Williams | Jan 9, 2026 at 7:55 AM EST

Biotech Could Be One of 2026’s Biggest Winners, and This ETF Is Perfectly Positioned

Biotech investors spent years waiting for the sector to recover from its brutal 2021 peak. That patience is finally paying…

Joey Frenette | Dec 14, 2025 at 10:58 AM EST

2 Brilliant Biotech ETFs to Watch in 2026

As the AI trade gets overheated and calls for some sort of bursting of the AI bubble grow louder, it…

John Seetoo | Dec 1, 2025 at 8:01 PM EST

Two Sector ETFs Are Quietly Outperforming the S&P 500 Without a Single AI Stock

Prognostications that the AI bubble is grossly overbought have been increasing. The fact that the Magnificent 7 AI stocks, such…

SPDR S&P Biotech ETF : XBI

XBI

$130.42

All XBI Articles

LABU Could Rip Higher if Biotech Finally Gets Its Long-Awaited Breakout

Equal-Weight ETFs Are the Play for Small-Cap Drug Development. Here’s How to Position Now

XBI vs. IBB: The Biotech ETF Showdown That Analysts Say Has a Clear Winner in 2026

This Biotech ETF Is Still Well Below Its 2021 Peak. Analysts Say That Is Exactly Why to Buy It.

Biotech Stocks Are Up About 35% in the Past Year and Analysts Say the Biggest Gains Are Still Ahead

MRNA, SRPT, and KRYS Phase 3 Data Will Shape XBI’s 2026 Performance

Biotech Could Be One of 2026’s Biggest Winners, and This ETF Is Perfectly Positioned

2 Brilliant Biotech ETFs to Watch in 2026

Two Sector ETFs Are Quietly Outperforming the S&P 500 Without a Single AI Stock

UFO ETF Faces a Critical Test: Can Pre-Profit Space Stocks Deliver on $1.85B Backlog

This High-Yield ETF Combines Bond Investing With Emerging Market Currencies

SoFi Stock Could Jump 26% as Market Overreacts to One Soft Segment

52% of Americans Are Building Wealth While Ignoring Their Greatest Risk

3 Reasons Retirees Should Not Enroll in Medicare Advantage for 2026

UFO ETF Faces a Critical Test: Can Pre-Profit Space Stocks Deliver on $1.85B Backlog

This High-Yield ETF Combines Bond Investing With Emerging Market Currencies

SPDR S&P Biotech ETF : XBI

XBI

$130.42

All XBI Articles

LABU Could Rip Higher if Biotech Finally Gets Its Long-Awaited Breakout

Equal-Weight ETFs Are the Play for Small-Cap Drug Development. Here’s How to Position Now

XBI vs. IBB: The Biotech ETF Showdown That Analysts Say Has a Clear Winner in 2026

This Biotech ETF Is Still Well Below Its 2021 Peak. Analysts Say That Is Exactly Why to Buy It.

Biotech Stocks Are Up About 35% in the Past Year and Analysts Say the Biggest Gains Are Still Ahead

MRNA, SRPT, and KRYS Phase 3 Data Will Shape XBI’s 2026 Performance

Biotech Could Be One of 2026’s Biggest Winners, and This ETF Is Perfectly Positioned

2 Brilliant Biotech ETFs to Watch in 2026

Two Sector ETFs Are Quietly Outperforming the S&P 500 Without a Single AI Stock

UFO ETF Faces a Critical Test: Can Pre-Profit Space Stocks Deliver on $1.85B Backlog

This High-Yield ETF Combines Bond Investing With Emerging Market Currencies

SoFi Stock Could Jump 26% as Market Overreacts to One Soft Segment

Featured Reads

52% of Americans Are Building Wealth While Ignoring Their Greatest Risk

3 Reasons Retirees Should Not Enroll in Medicare Advantage for 2026